[Economics of medicament therapies for osteoporosis].
For treatment of osteoporosis, medical costs range within 10% among administrations of alfacalcidol, raloxifene and weekly alendronate, because costs of the drugs are shared about 50% of medical costs. Medical costs of the patients suffered from mild lumbago, severe lumbago and femoral neck fracture are compared between the patients with and without the medicament therapies. Preventions of lumbago and fracture by the drugs reduce maximally 16.5% of medical costs. Economics of various therapies to prevent femoral neck fracture in whole Japan show that hip protector gains 73.1 billion yen and medicament therapies lose minimally 826.9 billion yen annually.
Hayashi
Yasufumi
Y
Tokyo Metropolitan Rehabilitation Hospital.
D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000191:economics*; D016527:Drug Costs; D005265:Femoral Neck Fractures / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D006887:Hydroxycholecalciferols / Q000008:administration & dosage / Q000191:economics; D007564:Japan; D017116:Low Back Pain / Q000209:etiology / Q000517:prevention & control; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy* / Q000191:economics*; D011482:Protective Devices / Q000191:economics; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage / Q000191:economics
D050071:Bone Density Conservation Agents; D006887:Hydroxycholecalciferols; D020849:Raloxifene Hydrochloride; C008088:alfacalcidol